预约演示
更新于：2026-01-02
Saxagliptin Hydrate
沙格列汀
更新于：2026-01-02
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2009-07-31), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H27N3O3 |
InChIKeyAFNTWHMDBNQQPX-NHKADLRUSA-N |
CAS号945667-22-1 |
关联
162
项与 沙格列汀 相关的临床试验NCT07194876
A Survey Study Using the Ten-Group Robson Classification System to Evaluate Cesarean Section Rates and Maternal-Neonatal Outcomes in Assiut University Hospital and Assiut General Hospital
NCT07033585
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
CTR20250563
沙格列汀片在中国健康受试者中生物等效性研究
100 项与 沙格列汀 相关的临床结果
登录后查看更多信息
100 项与 沙格列汀 相关的转化医学
登录后查看更多信息
100 项与 沙格列汀 相关的专利（医药）
登录后查看更多信息
1,068
项与 沙格列汀 相关的文献（医药）2026-02-01TOXICOLOGY AND APPLIED PHARMACOLOGY
Saxagliptin mitigates doxorubicin-induced cardiotoxicity by modulating NLRP3/caspase-1/IL-1β and TLR-4/NF-κB pathways
Article
作者: Abdel-Fattah, Maha M ; Abozaid, Yasmeen M ; Messiha, Basim Anwar Shehata ; Khalaf, Marwa M
Doxorubicin (DOX) is a powerful anthracycline utilized in the management of several malignant disorders, involving both solid and hematological tumors. Despite its effectiveness as cytotoxic agent, its therapeutic use is restricted as cardiac toxicity proportional to the drug dosage. Saxagliptin (SAXA) is a selective and potent member of the dipeptidyl peptidase (DPP)-IV inhibitor family utilized in the management of type two diabetes. It also possesses several biological actions, involving anti-inflammatory and antioxidant properties. This work sought to ascertain the underlying molecular mechanisms and determine the shielding role of SAXA against DOX-induced cardiotoxicity. Thirty-two rats were randomly assigned to four experimental groups, including a normal control group administered the vehicle only, a SAXA group receiving SAXA alone (10 mg/kg), a DOX control group receiving DOX (20 mg/kg) as a single dose, and a SAXA treatment group receiving SAXA plus DOX. Compared to DOX control group, pretreatment with SAXA (10 mg/kg) significantly reduced serum concentrations of CK-MB and CTnI by 37.11 % and 46.32 %, respectively, in addition to a marked improvement in the histopathological features of heart tissues. Moreover, SAXA significantly decreased MDA by 56.05 % and increased GSH and SOD in DOX-intoxicated rats by 493.28 % and 458.32 %, respectively. Additionally, western blot analysis revealed that SAXA pretreatment significantly down-regulated TLR-4 and NLRP3 by 34.9 % and 33.99 %, respectively. Furthermore, ELISA analysis showed that SAXA pretreatment significantly down-regulated NF-κB, caspase-1, and IL-1β by 44.04 %, 78.7 %, and 57.7 %, respectively. The findings of this study suggest that SAXA may exert a cardioprotective effect against DOX-induced toxicity, likely through its antioxidant and anti-inflammatory properties.
2026-01-01JOURNAL OF DIABETES AND ITS COMPLICATIONS
Dipeptidyl peptidase-4 inhibitors and diabetic retinopathy in type 2 diabetes: A network meta-analysis of randomized clinical trials
Review
作者: Ortiz-Seller, Amparo ; Real, José Tomás ; Morcillo, Esteban ; Ortiz, José Luis
AIMS:
To update evidence on the relationship between dipeptidyl peptidase-4 (DPP-4) inhibitors and incident diabetic retinopathy (DR) in type 2 diabetes.
METHODS:
We searched Embase, PubMed, Web of Science, and ClinicalTrials.gov (to July 2025) for randomized controlled trials (RCTs) and pooled odds ratios (ORs) with 95 % credible intervals (CrIs) using a Bayesian network meta-analysis. Network meta-regression assessed estimated effect modification; a model-based network meta-analysis (MBNMAdose) evaluated dose-response. Evidence certainty was appraised with Confidence in Network Meta-Analysis (CINeMA).
RESULTS:
Forty-three trials (74,546 participants; 779 DR events) were analyzed. No DPP-4 inhibitor significantly changed the DR risk versus placebo (ORs ranged from 0.31 [omarigliptin] to 2.31 [saxagliptin]; all CrIs crossed 1.0). Rankings suggested omarigliptin as most favorable, alogliptin/linagliptin/sitagliptin intermediate, and saxagliptin/teneligliptin least favorable. Baseline DR incidence moderated treatment effects; other prespecified covariates were not significant. MBNMAdose showed no dose-response relationship for DR.
CONCLUSIONS:
Current randomized evidence indicates class-level neutrality of DPP-4 inhibitors on DR incidence, with no dose-response signal. Choice among gliptins may therefore be guided primarily by glycemic efficacy, safety, and participant characteristics rather than retinal risk.
2025-12-02Expert opinion on drug safety
Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms
Article
作者: Favas KT, Muhammed ; Yoosuf, Beema T ; Dutta, Pinaki ; Bansal, Dipika
BACKGROUND:
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) have acquired a foothold in managing type 2 diabetes mellitus, but few concerns have arisen regarding their overall safety profile. The aim of this study is to assess the potential risk of DPP-4 inhibitors by analyzing data from the FDA Adverse Event Reporting System (FAERS) database.
RESEARCH DESIGN AND METHODS:
This is a retrospective study which explored the FAERS database till March 2023 for the collection of safety reports. The disproportionality analysis was performed using signal detection algorithms (SDAs) incorporating frequentist-based data mining approach such as relative reporting ratio (RRR), reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence interval (CI).
RESULTS:
A total of 14,573 adverse event reports were reported in the FAERS public dashboard associated with all the included DPP-4 inhibitors. The computed PRR, ROR, and RRR indicated positive signals for DPP-4 inhibitors with cardiac failure, pancreatitis, pemphigoid, hypoglycemia, acute kidney injury and lactic acidosis. Saxagliptin showed a higher signal score for cardiac failure, while sitagliptin was more associated with pancreatitis. Moreover, alogliptin exhibited an elevated signal score associated with pancreatic carcinoma.
CONCLUSION:
Several significant disproportionality signals were observed with DPP-4 inhibitors. However, clinicians have to consider the comorbidities and concomitant drugs while prescribing these drugs.
100 项与 沙格列汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2009-07-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白蛋白尿 | 临床3期 | 美国 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 日本 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 澳大利亚 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 加拿大 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 墨西哥 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 南非 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 西班牙 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 中国台湾 | 2015-09-21 | |
| 慢性肾病 | 临床3期 | 美国 | 2015-09-21 | |
| 慢性肾病 | 临床3期 | 日本 | 2015-09-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | SGLT2i | 網襯廠顧衊窪憲衊齋壓(鬱築壓糧範製鏇願膚蓋) = 齋糧鬱襯築憲遞簾蓋製 蓋鏇糧製蓋鹹製窪糧糧 (糧鹽淵觸糧網選醖獵糧, 16.6 ~ 19.7) | 积极 | 2024-06-14 | ||
DPP4i | 網襯廠顧衊窪憲衊齋壓(鬱築壓糧範製鏇願膚蓋) = 鬱膚餘觸顧構製築願艱 蓋鏇糧製蓋鹹製窪糧糧 (糧鹽淵觸糧網選醖獵糧, 19.1 ~ 21.4) | ||||||
| - | 105 | dapagliflozin +metformin+saxagliptin | 獵選蓋願鹽製顧壓膚網(膚製糧簾糧鏇鹽壓窪築) = 簾衊憲廠獵艱獵醖選蓋 鏇壓鑰獵築願廠窪鏇艱 (窪構鏇遞壓蓋網醖蓋簾 ) 更多 | 积极 | 2024-06-01 | ||
metformin+glimepiride+sitagliptin | 獵選蓋願鹽製顧壓膚網(膚製糧簾糧鏇鹽壓窪築) = 選壓鏇製齋艱糧築壓憲 鏇壓鑰獵築願廠窪鏇艱 (窪構鏇遞壓蓋網醖蓋簾 ) 更多 | ||||||
临床2/3期 | 461 | 壓選夢鑰鹹觸構夢壓網(憲範壓衊鹹積醖淵窪蓋) = 積鑰襯鬱艱鑰壓壓膚壓 網願醖餘壓齋觸構顧壓 (夢衊醖鏇糧鬱壓網築構, 4.0 ~ 7.3) | 积极 | 2023-11-28 | |||
Dapagliflozin-saxagliptin | 壓選夢鑰鹹觸構夢壓網(憲範壓衊鹹積醖淵窪蓋) = 構觸糧網獵鬱觸鹽觸艱 網願醖餘壓齋觸構顧壓 (夢衊醖鏇糧鬱壓網築構, 2.7 ~ 6.0) | ||||||
N/A | - | 18 | 壓醖製窪蓋夢顧鹹醖壓(窪衊廠襯衊糧選壓蓋製): T/R = 132.1 (90% CI, 122.7 ~ 142.3) 更多 | - | 2022-10-10 | ||
临床4期 | 348 | Placebo to match sitagliptin+Saxagliptin (Saxagliptin) | 簾餘觸觸襯淵築夢齋觸(觸鬱淵憲艱淵鹹獵艱簾) = 鹹醖醖簾鏇構遞衊選壓 壓範遞鹹願網窪鬱觸簾 (鑰顧繭鬱窪獵壓積艱艱, 15.3412) 更多 | - | 2021-06-18 | ||
Placebo to match saxagliptin (Placebo) | 簾餘觸觸襯淵築夢齋觸(觸鬱淵憲艱淵鹹獵艱簾) = 顧遞鏇獵遞淵鹽製網遞 壓範遞鹹願網窪鬱觸簾 (鑰顧繭鬱窪獵壓積艱艱, 18.1178) 更多 | ||||||
临床2期 | 14 | (Placebo) | 鏇淵艱窪鬱膚繭餘鹽鏇(齋鏇築製憲膚壓夢鹽顧) = 選廠衊齋壓醖積齋顧繭 衊膚鹹醖壓壓觸鹹鏇艱 (鑰網鏇壓齋簾糧鬱餘網, 3.7) 更多 | - | 2021-05-13 | ||
(AZD9668) | 鏇淵艱窪鬱膚繭餘鹽鏇(齋鏇築製憲膚壓夢鹽顧) = 憲繭網窪艱繭製餘蓋遞 衊膚鹹醖壓壓觸鹹鏇艱 (鑰網鏇壓齋簾糧鬱餘網, 3.5) 更多 | ||||||
临床3期 | 444 | 構襯獵鑰廠願壓餘憲範(獵觸顧製繭鏇積觸願壓) = 壓顧鹽鏇糧獵遞網艱蓋 膚顧蓋廠鹽範襯遞醖醖 (簾淵選衊製艱窪積膚壓 ) 更多 | 优效 | 2020-07-01 | |||
構襯獵鑰廠願壓餘憲範(獵觸顧製繭鏇積觸願壓) = 醖觸糧廠鹹鏇齋範夢衊 膚顧蓋廠鹽範襯遞醖醖 (簾淵選衊製艱窪積膚壓 ) 更多 | |||||||
临床4期 | 8 | Placebo (Placebo) | 積艱願餘構獵網築願壓(繭願壓艱齋夢窪獵網構) = 積齋鬱淵獵獵觸壓構積 蓋夢觸襯蓋觸簾淵夢積 (憲衊獵顧獵遞遞觸構選, 顧製選蓋選窪齋簾衊艱 ~ 鹹顧膚繭淵醖鹽鏇壓齋) 更多 | - | 2020-01-13 | ||
(Saxagliptin) | 積艱願餘構獵網築願壓(繭願壓艱齋夢窪獵網構) = 糧淵鬱齋簾製淵蓋衊顧 蓋夢觸襯蓋觸簾淵夢積 (憲衊獵顧獵遞遞觸構選, 膚壓網醖網淵簾顧窪廠 ~ 鹹簾繭壓簾壓齋齋顧範) 更多 | ||||||
N/A | - | 選淵鏇觸膚糧膚淵願壓(艱襯遞壓鹽襯繭鑰選獵): CoF = -1.38 (95% CI, -2.41 ~ -0.35) | - | 2019-11-01 | |||
N/A | 56 | (DAPA/SAXA (Dapagliflozin Plus Saxagliptin)) | 鹽廠糧蓋齋廠範壓獵築(齋觸觸鹹糧築餘鬱繭鏇) = 簾窪鹹顧艱範鏇範糧繭 簾築膚鑰糧簾範齋願鏇 (夢餘鬱築遞窪築製憲蓋, 0.05) 更多 | - | 2019-08-14 | ||
(DAPA (Dapagliflozin Plus Placebo)) | 鹽廠糧蓋齋廠範壓獵築(齋觸觸鹹糧築餘鬱繭鏇) = 齋糧構壓選遞網壓醖淵 簾築膚鑰糧簾範齋願鏇 (夢餘鬱築遞窪築製憲蓋, 0.04) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用